MRL Ventures Fund

MRL Ventures Fund

MRL Ventures Fund, LLC is Merck's independent early-stage bio-therapeutics venture capital fund.

MRL Ventures Fund, LLC is Merck's independent early-stage bio-therapeutics venture capital fund. The firm has been in operation since 2004, in Cambridge, Massachusetts, United States.

The firm is interested in investing in seed and early-stage therapeutics companies, and breakthrough sciences that are created to deliver new medicines that improve human health. MRL Ventures Fund is interested in investing during Series A through C rounds in companies such as Imgo BioSciences, Entrada Therapeutics, Rheostat Therapeutics, and Kymera Therapeutics.

Timeline

Funded Companies

Company
Description
Industry
Website
Location
Visterra

A company developing antibody-based biological medicines for kidney diseases and other chronic diseases. Visterra was acquired by Otsuka Pharmaceutical in 2018.

A therapeutics company founded in 2016 working in drug discovery and development using fungi. LifeMine uses genomics approaches to search for biosynthetic genes in eukaryotic microbes for the discovery of naturally inspired drugs to treat previously untreatable and significant chronic diseases.

Rheostat, located at 300 Technology Square, in Cambridge, Massachusetts is a biotech company developing treatments for neurodegenerative diseases by targeting mitophagy and autophagy pathways.

Kymera Therapeutics is a Cambridge, Massachusetts-based biotechnology company specialized in the field of targeted protein degradation.

Alector is a San Francisco-based biotechnology company.

Carisma Therapeutics is a Philadelphia County, Pennsylvania-based company.

9 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.